$Mural Oncology (MURA.US)$ NEWS Mural Oncology Presents Clin...
NEWS
Mural Oncology Presents Clinical Data from ARTISTRY-3 at the American Society of Clinical Oncology Annual Meeting
Mural Oncology presented data from its ARTISTRY-3 trial at the ASCO annual meeting, showing that less frequent dosing of nemvaleukin alfa (nemvaleukin), an engineered IL-2 cytokine, is well-tolerated and effective.
The trial shifted from five daily infusions to two infusions per three-week cycle, both as a single agent and in combination with pembrolizumab. Nemvaleukin showed promising pharmacodynamic effects, such as expansion of immune-stimulating CD8+ T cells and NK cells, with minimal expansion of immunosuppressive Tregs, and no new safety issues.
Preliminary data from ARTISTRY-6 cohorts are expected in 2025.
The trial shifted from five daily infusions to two infusions per three-week cycle, both as a single agent and in combination with pembrolizumab. Nemvaleukin showed promising pharmacodynamic effects, such as expansion of immune-stimulating CD8+ T cells and NK cells, with minimal expansion of immunosuppressive Tregs, and no new safety issues.
Preliminary data from ARTISTRY-6 cohorts are expected in 2025.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1037Followers
64Following
6990Visitors
Follow